Olivia Belbin

Jul 18, 2024 | nature.com | Juan Fortea |Daniel Alcolea |Olivia Belbin |Oriol Dols-Icardo |Laura Videla |Marc Suárez-Calvet | +4 more

replying to C. Pappalettera et al. Nat. Med. https://doi.org/10.1038/s41591-024-03158-5 (2024)Pappalettera et al.1 raise important points concerning our recent publication on APOE4 homozygotes2, specifically about the definition of Alzheimer’s disease (AD), resilience factors, and the ethical implications of diagnosing asymptomatic individuals.

Jun 17, 2024 | nature.com | Juan Fortea |Jordi Pegueroles |Daniel Alcolea |Olivia Belbin |Oriol Dols-Icardo |Laura Videla | +5 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-02931-w, published online 6 May 2024In the version of the article initially published, the title of Fig. 4 read “APOE3 homozygotes” and has now been amended to “APOE4 homozygotes” in the HTML and PDF versions of the article. About this articleFortea, J., Pegueroles, J., Alcolea, D. et al. Publisher Correction: APOE4 homozygosity represents a distinct genetic form of Alzheimer’s disease. Nat Med (2024).

May 6, 2024 | nature.com | Juan Fortea |Jordi Pegueroles |Daniel Alcolea |Olivia Belbin |Oriol Dols-Icardo |Laura Videla | +5 more

AbstractThis study aimed to evaluate the impact of APOE4 homozygosity on Alzheimer’s disease (AD) by examining its clinical, pathological and biomarker changes to see whether APOE4 homozygotes constitute a distinct, genetically determined form of AD. Data from the National Alzheimer’s Coordinating Center and five large cohorts with AD biomarkers were analyzed. The analysis included 3,297 individuals for the pathological study and 10,039 for the clinical study.